- Home
- LEGN
as 01-17-2025 4:00pm EST
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 6.0B | IPO Year: | 2020 |
| Target Price: | $80.62 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $30.17 - $70.13 | Next Earning Date: | 03-10-2025 |
| Revenue: | $520,183,000 | Revenue Growth: | 122.96% |
| Revenue Growth (this year): | 120.36% | Revenue Growth (next year): | 67.91% |
Latest Legend Biotech Corporation News
LEGN Breaking Stock News: Dive into LEGN Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Legend Biotech Corporation (LEGN): The Biotech Stock with Biggest Upside Potential
MT Newswires
12 days ago
RBC Trims Price Target on Legend Biotech to $84 From $86, Keeps Outperform Rating
MT Newswires
17 days ago
Karyopharm Therapeutics Names Lori Macomber CFO
MT Newswires
a month ago
Top Midday Decliners
MT Newswires
a month ago
Legend Biotech CFO Lori Macomber to Resign, Jessie Yeung Named Interim CFO
Simply Wall St.
a month ago
Exploring 3 High Growth Tech Stocks In The United States
GlobeNewswire
a month ago
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
TipRanks
a month ago
Legend Biotech’s CARVYKTI® Boosts Myeloma Treatment Success
Compare LEGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LEGN Legend Biotech Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.